Biomarkers to Fine-Tune Intrathecal Nicardipine for Brain Bleeding-Related Stroke
Official title: Development of Biomarkers to Optimize Intrathecal Nicardipine Treatment for Cerebral Vasospasm and Delayed Cerebral Ischemia after Subarachnoid Hemorrhage
Funded at Emory University · NIH-11385464 · Data updated 2026-11-12
Researchers are testing biomarkers to personalize intrathecal nicardipine treatment for patients after subarachnoid hemorrhage to prevent brain damage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 27, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $386,840 |
| NIH project number | 5R01NS130036-05 |
| Project ID | NIH-11385464 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with subarachnoid hemorrhage who are treated with intrathecal nicardipine and are being considered for biomarker-guided therapy.
✕Less likely to help
Patients who do not develop or require intrathecal nicardipine may not benefit from this biomarker approach.
What this research studies
This project aims to identify non-invasive biomarkers that help predict who will benefit most from intrathecal nicardipine after a subarachnoid hemorrhage. By using diffuse optical spectroscopy, the team hopes to tailor dosing and improve outcomes in patients at risk of vasospasm and delayed cerebral ischemia. The work builds on prior retrospective observations and focuses on translating biomarkers into clinical decision tools. The study is centered at Emory University with a focus on real-world SAH patients and their recovery trajectories.
Why it matters
Potential benefit: If successful, patients with subarachnoid hemorrhage could receive more personalized treatment, potentially reducing brain injury and improving recovery.
How similar studies have gone: Preliminary retrospective data in over 400 patients suggest intrathecal nicardipine is safe and effective, but prospective biomarker-driven selection is novel.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Sadan, Ofer — Emory University
- Study coordinator: Sadan, Ofer
Related research
Other NIH-funded projects on the same topics.
-
Cognitive screening after an aneurysmal brain bleed
Using patient questionnaires to find thinking and memory problems in people recovering from aneurysmal subarachnoid hemorrhage.
-
Blood test to predict delayed brain injury after an aneurysm bleed
This project is creating a blood test to spot which people who had a brain aneurysm bleed are likely to develop delayed brain injury in the days after the bleed.
-
3D brain blood vessel model to study subarachnoid hemorrhage and test therapies
A researcher will develop a 3D printed, biomimetic brain model to study subarachnoid hemorrhage and screen potential nanoparticle-based treatments.
-
Adropin as a shield for the brain after a brain hemorrhage
A potential treatment with adropin is being studied to protect brain cells after a subarachnoid hemorrhage and reduce stroke-like damage.
-
Manganese-based compound as a potential therapy for subarachnoid hemorrhage
A new manganese porphyrin-based drug is being explored as a possible treatment to reduce brain injury after a subarachnoid hemorrhage.
-
START Network for Promising Novel Drug Testing in Subarachnoid Hemorrhage
A network of three sites will test two potential treatments in a late-stage, animal model study of subarachnoid hemorrhage to help improve outcomes for patients who suffer this brain injury.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.